ClinicalTrials.gg
CompletedNCT02038647Updated Dec 27, 2018Results posted

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

A Phase 2 interventional study of Alisertib and Placebo in Small Cell Lung Cancer, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 61 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-27.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 629 studies in Small Cell Lung Carcinoma with a site in United States — 111 open to participants now, 182 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Enrollment
120th of 550
178 · median 55
Started
2014
with 18 others
Phase 2
186 of 629
24 open now
Registered
265th of 629
by date

Among the 629 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 120th largest by enrollment of the 550 interventional ones that give a count, is one of 19 that started in 2014, is one of 186 in phase 2, and was the 265th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

111 of the 629 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 629 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This is a two-arm, randomized, double-blind, placebo-controlled, multicenter, phase 2 study designed to is to determine if the combination treatment can improve progression free survival (defined as the time from the date of randomization to the date of first documentation of disease progression or death, whichever occurs first) when compared with placebo + paclitaxel.

Read the detailed description

The drug tested in this study is called alisertib. Alisertib is being tested to treat people who have Small Cell Lung Cancer (SCLC). This study determined the safety and efficacy for alisertib when given twice a day along with paclitaxel.

This open label study enrolled 178 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there is an urgent medical need) and participants were stratified at baseline as to whether brain mets were present or not; whether they were sensitive to prior therapy or were relapsed/refractory to prior therapy; and by world region:

  • Alisertib 40 mg + Paclitaxel 60 mg/m\^2
  • Paclitaxel 80 mg/m\^2 + Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient

All participants received treatment until their disease progressed or they experienced unacceptable alisertib-related toxicity.

This multi-center trial was conducted world-wide. The overall time to participate in this study was approximately up to 22 months. Participants made multiple visits to the clinic, and were contacted by telephone every month for 6 months after the end of treatment (EOT) for follow-up assessment of progression free survival and for overall survival every 2 months until death, study closure, or 14 months after randomization of the last participant.

03

Conditions studied

  • Small Cell Lung Cancer

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each participant must meet all the following inclusion criteria to be enrolled in the study:

  1. Male or female participants ≥ 18 years old.
  2. Have a pathologically (histology or cytology) confirmed diagnosis of SCLC.
  3. Have received and progressed after a platinum-based standard chemotherapy regimen for treatment of SCLC, either limited stage (LS) or extensive stage (ES).
  4. Have within ≤ 2 weeks before randomization. Clear radiographic evidence of disease progression after initial therapy should have been documented.
  5. (ECOG) performance status (PS) of 0 or 1 (PS 0-1).
  6. Participants with treated (surgery, whole or stereotactic brain radiation) are allowed provided the lesions have been stable for at least 2 weeks and the participant is off or is on a stable dose of steroids. Participants should be without neurologic dysfunction that would confound the evaluation of neurological and/or other AEs.

Exclusion criteria

Exclusion Criteria

Participants meeting any of the following exclusion criteria are not to be randomized to treatment:

  1. Any prior therapy for treatment of SCLC.
  2. Participants who ≥ 180 days after their response to first-line treatment.
  3. Prior treatment with an Aurora A specific-targeted or pan-Aurora-targeted agent, including alisertib, or any other agent.
  4. Prior treatment with paclitaxel or any other taxane agent.
  5. Known to Cremophor® EL, paclitaxel, or its components.
  6. Any comorbid condition or unresolved toxicity that would preclude administration of alisertib or weekly paclitaxel.
  7. Prior history of ≥ Grade 2 neurotoxicity that is not resolved to ≤ Grade 1.
  8. Participants with symptomatic and/or progressive or with carcinomatous meningitis.
  9. Treatment with enzyme inducers within 14 days prior to the first dose of alisertib and during study conduct. Major prohibited enzyme inducers include: phenytoin, carbamazepine, phenobarbital, rifampin, rifabutin, rifapentine, and St. John's wort.
  10. Inability to swallow alisertib or other orally administered medications.
  11. Requirement for administration of proton pump inhibitor (PPI), H2 antagonist, or pancreatic enzymes.
  12. Diagnosed with or treated for another within 2 years before the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease.
  13. Other severe acute or chronic medical or psychiatric condition(s) per protocol.
  14. History of myocardial infarction, unstable symptomatic ischemic heart disease, uncontrolled hypertension despite appropriate medical therapy, any ongoing cardiac arrhythmias of Grade > 2, thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (eg, pericardial effusion or restrictive cardiomyopathy) within 6 months before receiving the first dose of study drug.
  15. Known history of (HIV) infection, or .
  16. Surgery within 3 weeks (or 2 weeks for a minor surgery) before study enrollment and not fully recovered to baseline or to a stable clinical status.
  17. Participants who are pregnant, lactating, or do not agree to use effective methods of during the study treatment period through 6 months after the last dose of study drug per protocol.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
178 participants (actual)

Study arms

  • Experimental
    Alisertib (MLN8237) + Paclitaxel

    Alisertib 40 mg, tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 60 mg/m\^2 intravenously (IV) once a week for 3 weeks on Days 1, 8, and 15 in a 28-day until disease progression (Up to 17 Cycles).

    Drug: Alisertib · Drug: Paclitaxel

  • Placebo comparator
    Placebo + Paclitaxel

    Alisertib placebo-matching tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 80 mg/m\^2 IV once a week for 3 weeks on Days 1, 8, and 15 in a 28-day cycle until disease progression (Up to 22 Cycles).

    Drug: Placebo · Drug: Paclitaxel

Interventions

  • Alisertib tablets

    Also known as: MLN8237

  • DrugPlacebo

    Placebo matching tablets

  • Paclitaxel intravenous injection

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) as Determined by Investigator, Analyzed Using FDA Guidelines

    PFS is defined as time in days from start of study treatment to first documentation of objective tumor progression based on Investigator's assessment or up to death due to any cause, whichever occurs first based on Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. Progressive disease (PD) was defined as ≥20% increase in sum longest diameter (LD) in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Every cycle for first 6 months and then every 2 months until disease progression or death or up to data cut-off: 03 January 2016 (approximately 22 months)

Secondary outcomes

  1. Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with treatment. An AE can be any unfavorable and unintended sign (eg, clinically significant abnormal laboratory finding), symptom, or disease temporally associated with use of drug, whether or not it is considered related to drug. A treatment-emergent adverse event (TEAE) is defined as an AE with an onset that occurs after receiving study drug. A Serious Adverse Event (SAE) is any experience that suggests significant hazard, contraindication, side effect or precaution that:results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is congenital anomaly/birth defect or is medically significant per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.

    Time frame: From the first dose through 30 days after the last dose of study medication: data cut-off 03 January 2016 (Up to 10.8 months)

  2. Overall Survival (OS)

    OS was defined as the time in days from the date of randomization to the date of death due to any cause.

    Time frame: Contact every 2 months after EOT/disease progression until the sooner of death, study closure, or 14 months after the last participant was randomized up to data cut-off: 3 January 2016 (approximately 22 months)

  3. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who achieved CR or partial response (PR) as best response based on Investigator's assessment according to RECIST v 1.1. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as ≥ 30% decrease in sum of LD of target lesions in reference to Baseline sum LD.

    Time frame: Baseline until disease progression, death or EOT up to data cut-off: 03 January 2016 (approximately 9.8 months)

  4. Complete Response Rate (CRR)

    CRR is defined as the percentage of participants who achieved CR as best response and based on Investigator's assessment according to RECIST v 1.1. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.

    Time frame: Baseline until disease progression, death or EOT up to data cut-off: 03 January 2016 (approximately 9.8 months)

  5. Disease Control Rate (DCR)

    DCR was defined as the percentage of participants who achieved CR, PR, or SD (when SD was a minimum of 8 weeks in duration). Duration of SD was defined as the time from the date of randomization to the date of first documentation of disease progression for participants who achieved SD as their best overall response. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as ≥ 30% decrease in sum of LD of target lesions in reference to Baseline sum LD. PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Baseline until disease progression, death or EOT up to data cut-off: 03 January 2016 (approximately 9.8 months)

  6. Duration of Response (DOR)

    DOR was defined as the time from the date of first documentation of a PR or better to the date of first documentation of PD for responders. PR was defined as ≥ 30% decrease in sum of longest diameter (LD) of target lesions in reference to Baseline sum LD. PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From first documented response until disease progression until data cut-off 03 January 2016 (approximately 9.8 months)

  7. Change From Baseline in Symptom (QLQ-LC13 Cough Scale, QLQ-C30 Dyspnea Scale, QLQ-C30 Pain Scale) Score at Cycle 5

    European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 is 30-item questionnaire with 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (fatigue, nausea, vomiting and pain), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions use 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions use 7-point scale (1=very poor - 7=Excellent). Total Score=0-100 scale; for 5 functional scales and global quality-of-life scale, a higher score=a better level of functioning. For symptoms scale, higher score= higher level of symptoms. EORTC QLQ-LC13 is considered as standard instrument to assess the quality of life (QL) of lung cancer participants. Total Score=0-100. Higher score=increase in level of symptomatology. The change between (QLQ-LC13 Cough Scale, QLQ-C30 Dyspnea Scale, QLQ-C30 Pain Scale) score collected at Cycle 5 relative to baseline.

    Time frame: Baseline up to Cycle 5 (approximately 4.6 months)

  8. Percentage of Participants Experiencing Symptom Relief

    Percentage of participants experiencing symptom relief, including coughing relief, dyspnea relief, and pain relief. Coughing relief is defined as a decrease from baseline ≥ 10 in QLQ-LC13 cough scale/item score. Dyspnea relief is defined as a decrease from baseline ≥ 10 in QLQ-C30 dyspnea scale/item score. Pain relief is defined as a decrease from baseline ≥ 10 in QLQ-C30 pain scale score. EORTC QLQ-C30 is 30-item questionnaire with 5 functional scales, 1 global health status scale, 3 symptom scales, 6 single items. Total Score=0-100 scale; for 5 functional scales and global quality-of-life scale, a higher score=a better level of functioning. For symptoms scale, higher score= higher level of symptoms. EORTC QLQ-LC13 is considered as standard instrument to assess the QL of lung cancer participants. Total Score=0-100. Higher score=increase in level of symptomatology.

    Time frame: Baseline up to Cycle 11, data cut-off: 03 January 2016 (approximately 9.8 months)

  9. Time to Symptom Relief

    Time to symptom (coughing/dyspnea/pain) relief was defined as the time from the date of randomization to the date of first detection of coughing/dyspnea/pain relief, respectively.

    Time frame: Baseline up to Cycle 11, data cut-off: 03 January 2016 (approximately 9.8 months)

  10. Time to Symptom Progression

    Time to coughing/dyspnea/pain progression was defined as time from the date of randomization to date of first detection of progression. Coughing progression was defined as increase from baseline ≥10 in QLQ-LC13 cough scale/item score. Dyspnea progression was defined as increase from baseline ≥10 in QLQ-C30 dyspnea scale/item score. Pain progression was defined as increase from baseline ≥10 in QLQ-C30 pain scale score. EORTC QLQ-C30 is 30-item questionnaire with 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (fatigue, nausea, vomiting and pain), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The QLQ-LC13 is 13-item scale for assessing treatment-specific symptoms in lung cancer. Total Score= 0-100 scale; for 5 functional scales and global quality-of-life scale, higher score=better level of functioning. For symptoms scale, higher score=higher level of symptoms.

    Time frame: Baseline up to Cycle 11, data cut-off: 03 January 2016 (approximately 9.8 months)

  11. Observed Plasma Concentration for Alisertib

    Time frame: Day 1 pre-dose and 1, 2-4, 3-6, 10-11 hours post-dose; Day 8, 2 hours post-dose; Day 15, 6-9 hours (hrs) post-dose

  12. Observed Plasma Concentration for Paclitaxel

    Time frame: Day 1 pre-dose and 1, 2-4, 3-6, 10-11 hours post-dose; Day 8, 2 hours post-dose; Day 15, 6-9 hours post-dose

Other outcomes

  1. Biomarker Correlative Studies Including Circulating Tumor Cells and Circulating DNA Assessments

    Time frame: Day 1 cycle 1 in a 28-day cycle

  2. Health Related Quality of Life (HRQOL )

    Time frame: Baseline up to Cycle 11, data cut-off: 03 January 2016 (approximately 9.8 months)

07

Results

Posted Dec 27, 2018

Participant flow

Participants took part in the study at 54 investigative sites in the United States, Canada, European Union (Belgium, Czech Republic, France, Germany, Hungary, Italy, Poland and Spain) from 12 May 2014 to 10 July 2017. Data cutoff for the primary analysis was 3 January 2016.

Participant flow — Overall Study
MilestoneAlisertib + PaclitaxelPlacebo + Paclitaxel
Started8989
Completed00
Not completed8989
Withdrew: Progressive disease5059
Withdrew: Adverse event1810
Withdrew: Symptomatic deterioration77
Withdrew: Withdrawal by subject52
Withdrew: Not reported01
Withdrew: Ongoing at datacut910

Outcome measures

PrimaryProgression-Free Survival (PFS) as Determined by Investigator, Analyzed Using FDA Guidelines

PFS is defined as time in days from start of study treatment to first documentation of objective tumor progression based on Investigator's assessment or up to death due to any cause, whichever occurs first based on Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. Progressive disease (PD) was defined as ≥20% increase in sum longest diameter (LD) in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Every cycle for first 6 months and then every 2 months until disease progression or death or up to data cut-off: 03 January 2016 (approximately 22 months)
Reported as:
Median · days
Progression-Free Survival (PFS) as Determined by Investigator, Analyzed Using FDA Guidelines
daysAlisertib + PaclitaxelPlacebo + Paclitaxel
Progression-Free Survival (PFS) as Determined by Investigator, Analyzed Using FDA Guidelines101 (80 to 113)66 (53 to 83)
Statistical analysis
  • Alisertib + Paclitaxel vs Placebo + Paclitaxel · Log Rank · p = 0.113 (P-value tests the hypothesis of equal event times in both treatment arms obtained using the Log-rank test stratified by disease subtype as sensitive versus resistant/refractory and the presence of brain metastases.) · Hazard ratio (hr): 0.77 · 95% CI 0.557 to 1.067The stratification factors were: disease subtype as sensitive versus resistant/refractory and the presence of brain metastases (yes or no) with treatment (Alisertib + Paclitaxel vs Placebo + Paclitaxel) as a factor in the model.
SecondaryPercentage of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An Adverse Event (AE) is defined as any untoward medical occurrence in clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with treatment. An AE can be any unfavorable and unintended sign (eg, clinically significant abnormal laboratory finding), symptom, or disease temporally associated with use of drug, whether or not it is considered related to drug. A treatment-emergent adverse event (TEAE) is defined as an AE with an onset that occurs after receiving study drug. A Serious Adverse Event (SAE) is any experience that suggests significant hazard, contraindication, side effect or precaution that:results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is congenital anomaly/birth defect or is medically significant per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.

Time frame:
From the first dose through 30 days after the last dose of study medication: data cut-off 03 January 2016 (Up to 10.8 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
percentage of participantsAlisertib + PaclitaxelPlacebo + Paclitaxel
TEAEs9996
SAEs4431
SecondaryOverall Survival (OS)

OS was defined as the time in days from the date of randomization to the date of death due to any cause.

Time frame:
Contact every 2 months after EOT/disease progression until the sooner of death, study closure, or 14 months after the last participant was randomized up to data cut-off: 3 January 2016 (approximately 22 months)
Reported as:
Median · days
Overall Survival (OS)
daysAlisertib + PaclitaxelPlacebo + Paclitaxel
Overall Survival (OS)186 (150 to 219)165 (128 to 183)
Statistical analysis
  • Alisertib + Paclitaxel vs Placebo + Paclitaxel · Log Rank · p = 0.714 (P-value tests the hypothesis of equal event times in both treatment arms obtained using the Log-rank test stratified by disease subtype as sensitive versus resistant/refractory and the presence of brain metastases.) · Cox proportional hazard: 0.93 · 95% CI 0.652 to 1.341The stratification factors were: disease subtype as sensitive versus resistant/refractory and the presence of brain metastases (yes or no) with treatment (Alisertib + Paclitaxel vs Placebo + Paclitaxel) as a factor in the model.
SecondaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants who achieved CR or partial response (PR) as best response based on Investigator's assessment according to RECIST v 1.1. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as ≥ 30% decrease in sum of LD of target lesions in reference to Baseline sum LD.

Time frame:
Baseline until disease progression, death or EOT up to data cut-off: 03 January 2016 (approximately 9.8 months)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsAlisertib + PaclitaxelPlacebo + Paclitaxel
Overall Response Rate (ORR)22 (14 to 33)18 (11 to 28)
Statistical analysis
  • Alisertib + Paclitaxel vs Placebo + Paclitaxel · Weighted Cochran-Mantel-Haenszel test · p = 0.406 (Stratification factors were disease subtypes (sensitive versus resistant/refractory), the presence of brain metastases and region.) · Odds ratio (or): 0.74 · 95% CI 0.35 to 1.55Logistic regression using ORR as dependent variable, treatment arm as independent variable and disease subtype (sensitive vs resistant/refractory) and presence of brain metastases as stratification factors.
SecondaryComplete Response Rate (CRR)

CRR is defined as the percentage of participants who achieved CR as best response and based on Investigator's assessment according to RECIST v 1.1. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.

Time frame:
Baseline until disease progression, death or EOT up to data cut-off: 03 January 2016 (approximately 9.8 months)
Reported as:
Number · percentage of participants
Complete Response Rate (CRR)
percentage of participantsAlisertib + PaclitaxelPlacebo + Paclitaxel
Complete Response Rate (CRR)1 (1 to 6)0 (0 to 0)
Statistical analysis
  • Alisertib + Paclitaxel vs Placebo + Paclitaxel · Weighted Cochran-Mantel-Haenszel test · p = 0.283 (Stratification factors were disease subtypes (sensitive versus resistant/refractory), the presence of brain metastases and region.) · Odds ratio (or): 0.01 · 95% CI 0.01 to 9999.99Logistic regression using CRR as dependent variable, treatment arm as independent variable and disease subtype (sensitive vs resistant/refractory) and presence of brain metastases as stratification factors.
SecondaryDisease Control Rate (DCR)

DCR was defined as the percentage of participants who achieved CR, PR, or SD (when SD was a minimum of 8 weeks in duration). Duration of SD was defined as the time from the date of randomization to the date of first documentation of disease progression for participants who achieved SD as their best overall response. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as ≥ 30% decrease in sum of LD of target lesions in reference to Baseline sum LD. PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Baseline until disease progression, death or EOT up to data cut-off: 03 January 2016 (approximately 9.8 months)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsAlisertib + PaclitaxelPlacebo + Paclitaxel
Disease Control Rate (DCR)58 (47 to 69)46 (35 to 57)
Statistical analysis
  • Alisertib + Paclitaxel vs Placebo + Paclitaxel · Weighted Cochran-Mantel-Haenszel test · p = 0.077 (Stratification factors were disease subtypes (sensitive versus resistant/refractory), the presence of brain metastases and region.) · Odds ratio (or): 0.59 · 95% CI 0.32 to 1.08Logistic regression using DCR as dependent variable, treatment arm as independent variable and disease subtype (sensitive vs resistant/refractory) and presence of brain metastases as stratification factors.
SecondaryDuration of Response (DOR)

DOR was defined as the time from the date of first documentation of a PR or better to the date of first documentation of PD for responders. PR was defined as ≥ 30% decrease in sum of longest diameter (LD) of target lesions in reference to Baseline sum LD. PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From first documented response until disease progression until data cut-off 03 January 2016 (approximately 9.8 months)
Reported as:
Median · days
Duration of Response (DOR)
daysAlisertib + PaclitaxelPlacebo + Paclitaxel
Duration of Response (DOR)96 (84 to 141)85 (58 to 177)
SecondaryChange From Baseline in Symptom (QLQ-LC13 Cough Scale, QLQ-C30 Dyspnea Scale, QLQ-C30 Pain Scale) Score at Cycle 5

European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 is 30-item questionnaire with 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (fatigue, nausea, vomiting and pain), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions use 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions use 7-point scale (1=very poor - 7=Excellent). Total Score=0-100 scale; for 5 functional scales and global quality-of-life scale, a higher score=a better level of functioning. For symptoms scale, higher score= higher level of symptoms. EORTC QLQ-LC13 is considered as standard instrument to assess the quality of life (QL) of lung cancer participants. Total Score=0-100. Higher score=increase in level of symptomatology. The change between (QLQ-LC13 Cough Scale, QLQ-C30 Dyspnea Scale, QLQ-C30 Pain Scale) score collected at Cycle 5 relative to baseline.

Time frame:
Baseline up to Cycle 5 (approximately 4.6 months)
Reported as:
Least squares mean · score on a scale
Change From Baseline in Symptom (QLQ-LC13 Cough Scale, QLQ-C30 Dyspnea Scale, QLQ-C30 Pain Scale) Score at Cycle 5
score on a scaleAlisertib + PaclitaxelPlacebo + Paclitaxel
Change at Cycle 5, QLQ-LC-13 Cough Scale-10.94 ± 3.078.07 ± 6.04
Change at Cycle 5, QLQ-C30 Dyspnea Scale-3.48 ± 4.25-1.09 ± 2.92
Change at Cycle 5, QLQ-C30 Pain Scale-4.82 ± 4.86-4.88 ± 5.16
SecondaryPercentage of Participants Experiencing Symptom Relief

Percentage of participants experiencing symptom relief, including coughing relief, dyspnea relief, and pain relief. Coughing relief is defined as a decrease from baseline ≥ 10 in QLQ-LC13 cough scale/item score. Dyspnea relief is defined as a decrease from baseline ≥ 10 in QLQ-C30 dyspnea scale/item score. Pain relief is defined as a decrease from baseline ≥ 10 in QLQ-C30 pain scale score. EORTC QLQ-C30 is 30-item questionnaire with 5 functional scales, 1 global health status scale, 3 symptom scales, 6 single items. Total Score=0-100 scale; for 5 functional scales and global quality-of-life scale, a higher score=a better level of functioning. For symptoms scale, higher score= higher level of symptoms. EORTC QLQ-LC13 is considered as standard instrument to assess the QL of lung cancer participants. Total Score=0-100. Higher score=increase in level of symptomatology.

Time frame:
Baseline up to Cycle 11, data cut-off: 03 January 2016 (approximately 9.8 months)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Symptom Relief
percentage of participantsAlisertib + PaclitaxelPlacebo + Paclitaxel
Coughing Relief28 (19 to 39)24 (15 to 34)
Dyspnea Relief31 (22 to 42)16 (9 to 25)
Pain Relief39 (29 to 50)36 (26 to 47)
SecondaryTime to Symptom Relief

Time to symptom (coughing/dyspnea/pain) relief was defined as the time from the date of randomization to the date of first detection of coughing/dyspnea/pain relief, respectively.

Time frame:
Baseline up to Cycle 11, data cut-off: 03 January 2016 (approximately 9.8 months)
Reported as:
Median · months
Time to Symptom Relief
monthsAlisertib + PaclitaxelPlacebo + Paclitaxel
Time to Coughing ReliefNA (7.6 to NA)NA (NA to NA)
Time to Dyspnea ReliefNA (NA to NA)NA (NA to NA)
Time to Pain Relief3.0 (1.9 to NA)3.7 (1.1 to NA)
SecondaryTime to Symptom Progression

Time to coughing/dyspnea/pain progression was defined as time from the date of randomization to date of first detection of progression. Coughing progression was defined as increase from baseline ≥10 in QLQ-LC13 cough scale/item score. Dyspnea progression was defined as increase from baseline ≥10 in QLQ-C30 dyspnea scale/item score. Pain progression was defined as increase from baseline ≥10 in QLQ-C30 pain scale score. EORTC QLQ-C30 is 30-item questionnaire with 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (fatigue, nausea, vomiting and pain), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The QLQ-LC13 is 13-item scale for assessing treatment-specific symptoms in lung cancer. Total Score= 0-100 scale; for 5 functional scales and global quality-of-life scale, higher score=better level of functioning. For symptoms scale, higher score=higher level of symptoms.

Time frame:
Baseline up to Cycle 11, data cut-off: 03 January 2016 (approximately 9.8 months)
Reported as:
Median · months
Time to Symptom Progression
monthsAlisertib + PaclitaxelPlacebo + Paclitaxel
Time to Coughing ProgressionNA (NA to NA)2.8 (2.2 to 6.3)
Time to Dyspnea Progression3.7 (1.9 to NA)4.6 (1.9 to 6.3)
Time to Pain Progression2.9 (2.1 to NA)2.8 (1.9 to NA)
SecondaryObserved Plasma Concentration for Alisertib
Time frame:
Day 1 pre-dose and 1, 2-4, 3-6, 10-11 hours post-dose; Day 8, 2 hours post-dose; Day 15, 6-9 hours (hrs) post-dose
Reported as:
Mean · nM
Observed Plasma Concentration for Alisertib
nMAlisertib + Paclitaxel
Cycle 1, Day 1, Pre-Dose0 ± 0
Cycle 1, Day 1, 1 hr Post-Dose495.37 ± 663.456
Cycle 1, Day 1, 2-4 hrs Post-Dose861.18 ± 616.951
Cycle 1, Day 1, 3-6 hrs Post-Dose1048.88 ± 716.447
Cycle 1, Day 1, 10-11 hrs Post-Dose539.15 ± 291.170
Cycle 1, Day 8, 2 hrs Post-Dose897.41 ± 816.387
Cycle 1, Day 15, 6-9 hrs Post-Dose (1st Sample)1102.93 ± 612.265
Cycle 1, Day 15, 6-9 hrs Post-Dose (2nd Sample)976.92 ± 572.090
SecondaryObserved Plasma Concentration for Paclitaxel
Time frame:
Day 1 pre-dose and 1, 2-4, 3-6, 10-11 hours post-dose; Day 8, 2 hours post-dose; Day 15, 6-9 hours post-dose

No measurements were reported for this outcome.

Other pre-specifiedBiomarker Correlative Studies Including Circulating Tumor Cells and Circulating DNA Assessments
Time frame:
Day 1 cycle 1 in a 28-day cycle

No measurements were reported for this outcome.

Other pre-specifiedHealth Related Quality of Life (HRQOL )
Time frame:
Baseline up to Cycle 11, data cut-off: 03 January 2016 (approximately 9.8 months)

No measurements were reported for this outcome.

Adverse events

Collected over First dose of study drug through 30 days after the last dose of study drug (Up to 646 Days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alisertib + Paclitaxel12/87 (13.8%)39/87 (44.8%)85/87 (97.7%)
Placebo + Paclitaxel11/89 (12.4%)30/89 (33.7%)80/89 (89.9%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventAlisertib + PaclitaxelPlacebo + Paclitaxel
Febrile neutropeniaBlood and lymphatic system disorders9/870/89
Small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/876/89
NeutropeniaBlood and lymphatic system disorders5/870/89
DiarrhoeaGastrointestinal disorders5/870/89
StomatitisGastrointestinal disorders4/871/89
PneumoniaInfections and infestations3/871/89
Respiratory failureRespiratory, thoracic and mediastinal disorders3/870/89
General physical health deteriorationGeneral disorders3/871/89
AnaemiaBlood and lymphatic system disorders2/871/89
Neutropenic sepsisInfections and infestations2/870/89
Most frequent other events
Showing 10 of 53
Most frequent other events
EventAlisertib + PaclitaxelPlacebo + Paclitaxel
DiarrhoeaGastrointestinal disorders48/8718/89
NeutropeniaBlood and lymphatic system disorders41/877/89
FatigueGeneral disorders38/8728/89
AnaemiaBlood and lymphatic system disorders38/8718/89
NauseaGastrointestinal disorders30/8730/89
Decreased appetiteMetabolism and nutrition disorders29/8719/89
VomitingGastrointestinal disorders28/8719/89
StomatitisGastrointestinal disorders27/876/89
DyspnoeaRespiratory, thoracic and mediastinal disorders21/8719/89
ConstipationGastrointestinal disorders8/8721/89

Baseline characteristics

The ITT population was defined as all participants who were randomized to study treatment, whether or not any treatment was administered.

Age, Continuous
Age, Continuous(years)Alisertib + PaclitaxelPlacebo + PaclitaxelTotal
Mean61.8 ± 8.5563.4 ± 8.5662.6 ± 8.57
Sex: Female, Male
Sex: Female, Male(Participants)Alisertib + PaclitaxelPlacebo + PaclitaxelTotal
Female383977
Male5150101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Alisertib + PaclitaxelPlacebo + PaclitaxelTotal
Hispanic or Latino235
Not Hispanic or Latino8184165
Unknown or Not Reported617
Missing011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Alisertib + PaclitaxelPlacebo + PaclitaxelTotal
White8383166
Black or African American325
Not reported224
Asian101
Other011
Missing011
Region of Enrollment
Region of Enrollment(participants)Alisertib + PaclitaxelPlacebo + PaclitaxelTotal
Belgium8816
Czech Republic6511
France7512
Germany213
Hungary161531
Italy202
Poland134
Spain61117
Canada6612
United States353570
Height
Height(cm)Alisertib + PaclitaxelPlacebo + PaclitaxelTotal
Mean169.5 ± 10.43168.8 ± 9.52169.2 ± 9.96
Weight
Weight(kg)Alisertib + PaclitaxelPlacebo + PaclitaxelTotal
Mean78.47 ± 20.56175.26 ± 17.60276.87 ± 19.153
Body Surface Area
Body Surface Area(m^2)Alisertib + PaclitaxelPlacebo + PaclitaxelTotal
Mean1.911 ± 0.28291.872 ± 0.24331.891 ± 0.2637
08

Study locations

61 sites
  • Los Angeles, California, United States
  • Sacramento, California, United States
  • New Haven, Connecticut, United States
  • Washington, District of Columbia, United States
  • Boca Raton, Florida, United States
  • Hollywood, Florida, United States
  • Orlando, Florida, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Detroit, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Cleveland, Ohio, United States
  • Hershey, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • Seattle, Washington, United States
  • Edegem, Belgium
  • Gent, Belgium
  • Kortrijk, Belgium
  • Leuven, Belgium
  • Mons, Belgium
  • Roeselare, Belgium
  • Edmonton, Alberta, Canada
  • Hamilton, Ontario, Canada
  • Greenfield Park, Canada
  • Olomouc, Czechia
  • Ostrava, Czechia
  • Praha, Czechia
  • Usti Nad Labem, Czechia
  • Grenoble, France
  • Lyon, France
  • Marseille, France
  • Paris, France
  • Pessac, France
  • Rennes, France
  • Berlin, Germany
  • Frankfurt, Germany
  • Freiburg, Germany
  • Luebeck, Germany
  • Budapest, Hungary
  • Farkasgyepu, Hungary
  • Szolnok, Hungary
  • Tatabanya, Hungary
  • Torokbalint, Hungary
  • Milano, Italy
  • Orbassano, Italy
  • Parma, Italy
  • Gdansk, Poland
  • Mrozy, Poland
  • Warszawa, Poland
  • Wodzislaw Slaski, Poland
  • A Coruna, Spain
  • Barcelona, Spain
  • Girona, Spain
  • Madrid, Spain
  • Sevilla, Spain
09

References and documents

Publications

  • Owonikoko TK, Niu H, Nackaerts K, Csoszi T, Ostoros G, Mark Z, Baik C, Joy AA, Chouaid C, Jaime JC, Kolek V, Majem M, Roubec J, Santos ES, Chiang AC, Speranza G, Belani CP, Chiappori A, Patel MR, Czebe K, Byers L, Bahamon B, Li C, Sheldon-Waniga E, Kong EF, Williams M, Badola S, Shin H, Bedford L, Ecsedy JA, Bryant M, Jones S, Simmons J, Leonard EJ, Ullmann CD, Spigel DR; C14018 study investigators. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses. J Thorac Oncol. 2020 Feb;15(2):274-287. doi: 10.1016/j.jtho.2019.10.013. Epub 2019 Oct 23. PubMed 31655296 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Jan 2016, 19 months.

Results were first posted in Dec 2018, 2 years 11 months after primary completion.

Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's 19 months is below that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2013
First posted
Jan 16, 2014
StartActual
May 12, 2014
Primary completionActual
Jan 3, 2016
CompletionActual
Jul 10, 2017
Results first posted
Dec 27, 2018
Last update
Dec 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02038647
Responsible party
Sponsor
First posted
Jan 16, 2014
Start date
May 12, 2014
Primary completion
Jan 3, 2016
Completion
Jul 10, 2017
Results posted
Dec 27, 2018
Last update
Dec 27, 2018

Study contacts

Medical Director Clinical Science
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion